-+ 0.00%
-+ 0.00%
-+ 0.00%

US FDA ADVISERS SAY EFFICACY RESULTS FROM REPLIMUNE’S SKIN CANCER DRUG STUDY ARE EVALUABLE AND CLINICALLY MEANINGFUL

Reuters·07/30/2026 20:48:04

Please log in to view news